# Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

> **NCT02109406** · PHASE2 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** AZD2115 Dose 1
- **DRUG:** AZD 2115, Dose 2
- **DRUG:** Placebo MDI

## Key facts

- **NCT ID:** NCT02109406
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109406, "Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02109406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*